Loading
A phase 2 trial of Fruquintinib, Trifluridine/tipiracil in colorectal cancer, run by Criterium, Inc., now recruiting.
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06992258 by Criterium, Inc., with 120 participants planned, started 2025-10-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Trifluridine/tipiracil, Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Colorectal cancer.
Shares Trifluridine/tipiracil, Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Cytotoxic chemotherapy.
Shares Fruquintinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Cytotoxic chemotherapy.
Shares Trifluridine/tipiracil, Anti-angiogenic therapy, Cytotoxic chemotherapy, Colorectal cancer.